Dengue vaccine study aims to unlock immune secrets
NCT ID NCT07158190
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how the Takeda dengue vaccine (TAK-003) activates T-cells, a key part of the immune system. Researchers will vaccinate 30 healthy adults and analyze their T-cell and antibody responses over 26 weeks. The goal is to find reliable markers of protection, which could improve future dengue vaccines and help prevent severe disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK003 (live attenuated tetravalent dengue vaccine)
What this could lead to
If successful, this could identify immune markers that predict protection, helping improve dengue vaccines and reduce severe disease risk.
What could go wrong
This is a small, early-stage study (30 participants) focused on immune responses, not on proving the vaccine works. Results may not apply to larger populations or real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENGUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione Policlinico Universtiario Agostino Gemelli IRCCS
Rome, Roma, 00168, Italy